Anthera Pharmaceutic (ANTH) 2.83 $ANTH
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:25AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) moved big last session, as its shares jumped almost 8% on the day.
ANTH: 2.83 (-0.05), GERN: 2.72 (+0.03)
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
GlobeNewswire - Tue Aug 16, 3:33PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer. In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and in drug development to lead the blisibimod lupus program and Sollpura program, with both programs expected to report out topline data in the fourth quarter of this year. He will also have responsibility for the development of additional indications for blisibimod in diseases such as IgA nephropathy and cystic fibrosis and for Sollpura in celiac disease and other diseases. In addition, he will bring extensive experience with FDA and European filings to work closely with our regulatory team in preparing the Biologics License Applications (BLA) for both Sollpura and blisibimod.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura(TM)
GlobeNewswire - Tue Aug 16, 7:47AM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura(TM) in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had "no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter."
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
GlobeNewswire - Tue Aug 09, 7:35AM CDT
-- Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura(TM)
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
GlobeNewswire - Wed Aug 03, 3:19PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating blisibimod for the treatment of systemic lupus erythematosus, received their final study dose on July 27th. As described in the protocol, patients are followed for eight weeks after their last dose at which time the final safety data is collected. Due to timing of this final visit, the company expects topline efficacy and safety data will be available prior to the annual American College of Rheumatology Annual Meeting in November.
ANTH: 2.83 (-0.05)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 6.72 (-0.06), PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), NERV: 12.14 (-0.08)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.72 (-0.06), PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), NERV: 12.14 (-0.08)
Can the Rally in Anthera (ANTH) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:54AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) has been on the move lately as the stock has risen by 22.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
ANTH: 2.83 (-0.05)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), VTAE: 6.86 (-0.05), ITCI: 40.72 (+0.38)
CymaBay Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter ended March 31, 2016.
ANTH: 2.83 (-0.05), CBAY: 2.37 (-0.04)
Anthera reports 1Q loss
Automated Insights - Mon May 09, 7:47AM CDT
HAYWARD, Calif. (AP) _ Anthera Pharmaceuticals Inc. (ANTH) on Monday reported a loss of $11.7 million in its first quarter.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 7:38AM CDT
-- SOLUTION clinical study of Sollpura(TM) expanded to Europe, Israel and Canada in addition to ongoing US enrollment
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
GlobeNewswire - Wed Apr 27, 3:06PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors.
ANTH: 2.83 (-0.05)
Greenphire Empowers Orphan Drug and Rare Disease Clinical Research
PR Newswire - Tue Apr 19, 7:07AM CDT
Greenphire, the global leader in clinical payment solutions, today announced that its ClinCard Travel Module solution continues to empower clinical research in the orphan drug and rare disease market. With this announcement, Greenphire has expanded its client partners to include Anthera Pharmaceuticals, a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
ANTH: 2.83 (-0.05)
CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Tue Mar 29, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2015.
ANTH: 2.83 (-0.05), CBAY: 2.37 (-0.04)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.71 (-0.06), DRNA: 3.10 (-0.05), INCY: 80.84 (-0.26), LLY: 77.16 (-0.59), STML: 8.00 (-0.18), SNTA: 0.34 (+0.07), ANTH: 2.83 (-0.05), EXEL: 11.08 (-0.07)
Nephropathy Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq5b5l/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Nephropathy Overview - Therapeutics Development - Pipeline Products for Nephropathy - Overview - Pipeline Products for Nephropathy - Comparative Analysis - Nephropathy - Therapeutics under Development by Companies - Nephropathy - Therapeutics under Investigation by Universities/Institutes - Nephropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Nephropathy - Products under Development by Companies - Nephropathy - Products under Investigation by Universities/Institutes - Nephropathy - Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - ChemoCentryx, Inc. - Complexa, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/hq...ephropathy
ANTH: 2.83 (-0.05), CCXI: 5.05 (+0.05)
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer
GlobeNewswire - Tue Jan 05, 4:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer. In this role Mr. Thompson will oversee both of Anthera's late stage development programs and commercial preparation efforts. Anthera also announced the appointment of Chuck Olson, D.Sc. to the position of Chief Technology Officer replacing Debra Odink, Ph.D. who will continue to support the company in a key advisory role.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial Results
GlobeNewswire - Wed Oct 28, 2:03PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the following healthcare conferences:
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:25AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) moved big last session, as its shares jumped almost 8% on the day.
ANTH: 2.83 (-0.05), GERN: 2.72 (+0.03)
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
GlobeNewswire - Tue Aug 16, 3:33PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer. In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and in drug development to lead the blisibimod lupus program and Sollpura program, with both programs expected to report out topline data in the fourth quarter of this year. He will also have responsibility for the development of additional indications for blisibimod in diseases such as IgA nephropathy and cystic fibrosis and for Sollpura in celiac disease and other diseases. In addition, he will bring extensive experience with FDA and European filings to work closely with our regulatory team in preparing the Biologics License Applications (BLA) for both Sollpura and blisibimod.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura(TM)
GlobeNewswire - Tue Aug 16, 7:47AM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura(TM) in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had "no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter."
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
GlobeNewswire - Tue Aug 09, 7:35AM CDT
-- Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura(TM)
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
GlobeNewswire - Wed Aug 03, 3:19PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating blisibimod for the treatment of systemic lupus erythematosus, received their final study dose on July 27th. As described in the protocol, patients are followed for eight weeks after their last dose at which time the final safety data is collected. Due to timing of this final visit, the company expects topline efficacy and safety data will be available prior to the annual American College of Rheumatology Annual Meeting in November.
ANTH: 2.83 (-0.05)
Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Tue Aug 02, 9:02AM CDT
The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. Stock-Callers.com now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:
TRVN: 6.72 (-0.06), PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), NERV: 12.14 (-0.08)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.72 (-0.06), PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), NERV: 12.14 (-0.08)
Can the Rally in Anthera (ANTH) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:54AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) has been on the move lately as the stock has risen by 22.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
ANTH: 2.83 (-0.05)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 20.66 (+0.30), ANTH: 2.83 (-0.05), VTAE: 6.86 (-0.05), ITCI: 40.72 (+0.38)
CymaBay Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter ended March 31, 2016.
ANTH: 2.83 (-0.05), CBAY: 2.37 (-0.04)
Anthera reports 1Q loss
Automated Insights - Mon May 09, 7:47AM CDT
HAYWARD, Calif. (AP) _ Anthera Pharmaceuticals Inc. (ANTH) on Monday reported a loss of $11.7 million in its first quarter.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 7:38AM CDT
-- SOLUTION clinical study of Sollpura(TM) expanded to Europe, Israel and Canada in addition to ongoing US enrollment
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
GlobeNewswire - Wed Apr 27, 3:06PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors.
ANTH: 2.83 (-0.05)
Greenphire Empowers Orphan Drug and Rare Disease Clinical Research
PR Newswire - Tue Apr 19, 7:07AM CDT
Greenphire, the global leader in clinical payment solutions, today announced that its ClinCard Travel Module solution continues to empower clinical research in the orphan drug and rare disease market. With this announcement, Greenphire has expanded its client partners to include Anthera Pharmaceuticals, a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
ANTH: 2.83 (-0.05)
CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Tue Mar 29, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2015.
ANTH: 2.83 (-0.05), CBAY: 2.37 (-0.04)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.71 (-0.06), DRNA: 3.10 (-0.05), INCY: 80.84 (-0.26), LLY: 77.16 (-0.59), STML: 8.00 (-0.18), SNTA: 0.34 (+0.07), ANTH: 2.83 (-0.05), EXEL: 11.08 (-0.07)
Nephropathy Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq5b5l/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Nephropathy Overview - Therapeutics Development - Pipeline Products for Nephropathy - Overview - Pipeline Products for Nephropathy - Comparative Analysis - Nephropathy - Therapeutics under Development by Companies - Nephropathy - Therapeutics under Investigation by Universities/Institutes - Nephropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Nephropathy - Products under Development by Companies - Nephropathy - Products under Investigation by Universities/Institutes - Nephropathy - Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - ChemoCentryx, Inc. - Complexa, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/hq...ephropathy
ANTH: 2.83 (-0.05), CCXI: 5.05 (+0.05)
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer
GlobeNewswire - Tue Jan 05, 4:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer. In this role Mr. Thompson will oversee both of Anthera's late stage development programs and commercial preparation efforts. Anthera also announced the appointment of Chuck Olson, D.Sc. to the position of Chief Technology Officer replacing Debra Odink, Ph.D. who will continue to support the company in a key advisory role.
ANTH: 2.83 (-0.05)
Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial Results
GlobeNewswire - Wed Oct 28, 2:03PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the following healthcare conferences:
ANTH: 2.83 (-0.05)
